Pfizer/Wyeth Merger Would Offer Diversification, Switch Outlet
This article was originally published in The Tan Sheet
Executive Summary
Pfizer's potential acquisition of Wyeth could swing the company back to a diversified portfolio - including the return of a consumer health division -and help offset a dwindling pipeline and the looming generic competition that threatens Rx sales, analysts say
You may also be interested in...
Sanofi-Aventis Acquisitions Could Double OTC Sales By 2014
French drug maker Sanofi-Aventis is establishing an OTC division and plans to double revenues from nonprescription drug products within five years
P&G Focuses On Consumer Health, “Deemphasizes” Pharma
Procter & Gamble says consumer health trends are on its side as the company increases focus on its consumer health business and moves away from pharmaceuticals
Pfizer Pulls Back On European Viagra Switch As Questions Linger
Pfizer withdraws its application to switch Viagra 50 mg from prescription to nonprescription status through the European Medicines Agency's centralized process, the company said Nov. 20